All In Biotech

Drug Trial Radar · NCT01659866

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP)

Last checked: Nov 19, 2026Latest source record: Jun 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

563

Actual

Start

Aug 2012

Primary completion

Aug 2015

Study completion Aug 2016

Sponsor

Lead sponsor
Northwestern UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 8, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 30 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being conducted in men scheduled to undergo transrectal ultrasound-guided prostate biopsy (TRUSP). Traditionally prior to prostate biopsy, an antibiotic, ciprofloxacin, has been given to men to prevent biopsy-related infections. In recent years as ciprofloxacin resistance has increased in the community, more and more men are becoming infected with ciprofloxacin-resistant bacteria after prostate biopsy. This study is being done to determine if obtaining rectal swab cultures and choosing antibiotics based on these culture results will result in fewer infectious complications than giving all men ciprofloxacin. The investigators will compare 2 groups: men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy, and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative antibiotics based on their culture results. Our hypothesis is that these 2 groups will have equal numbers of post-biopsy infectious complications and both groups will have fewer infectious complications than a historical group who received empiric ciprofloxacin without the benefit of rectal swab culture results.

Conditions

  • Infection

Interventions

  • CiprofloxacinDrug

    500 mg orally 2 hours before prostate biopsy

  • trimethoprim-sulfamethoxazoleDrug

    1 double strength tablet orally 2 hours before the procedure and again 12 hours later

  • cefuroximeDrug

    500 mg orally 2 hours before the procedure then again 12 hours later

  • ceftriaxoneDrug

    500 mg intramuscularly 2 hours before the procedure

  • gentamicinDrug

    2 mg/kg intramuscularly 2 hours before the procedure

  • amikacinDrug

    5 mg/kg intramuscularly 2 hours before the procedure

  • aztreonamDrug

    500 mg intramuscularly 2 hours before the procedure

  • imipenemDrug

    500 mg intramuscularly 2 hours before the procedure

  • ceftriaxoneDrug

    2000 mg intravenously 1 hour before the procedure

  • gentamicinDrug

    2 mg/kg intravenously 1 hour before the procedure

  • amikacinDrug

    5 mg/kg intravenously 1 hour before the procedure

  • aztreonamDrug

    2000 mg intravenously 1 hour before the procedure

  • imipenemDrug

    1000 mg intravenously 1 hour before the procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Post-biopsy Infection.Time frame: 30 days post-biopsy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwestern University Department of Urology

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.